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Abstract Glycation is important in the development of com-
plications of diabetes mellitus andmay have a central role in the
well-described glycaemic memory effect in developing these
complications. Skin fluorescence has emerged over the last de-
cade as a non-invasive method for assessing accumulation of
advanced glycation endproducts. Skin fluorescence is indepen-
dently related to micro- and macrovascular complications in
both type 1 and type 2 diabetes mellitus and is associated with
mortality in type 2 diabetes. The relation between skin fluores-
cence and cardiovascular disease also extends to other condi-
tions with increased tissue AGE levels, such as renal failure.
Besides cardiovascular complications, skin fluorescence has
been associated, more recently, with other prevalent conditions
in diabetes, such as brain atrophy and depression. Furthermore,
skin fluorescence is related to past long-term glycaemic control
and clinical markers of cardiovascular disease. This review will
discuss the technique of skin fluorescence, its validation as a
marker of tissue AGE accumulation, and its use as a clinical
tool for the prediction of long-term complications in diabetes
mellitus.
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Introduction
Worldwide, the prevalence of diabetes mellitus is increasing at
an alarming rate, mainly because of an increasing incidence of
type 2 diabetes mellitus (T2DM) [1]. The concomitant rising
medical costs are largely attributable to treatment of long-term
complications caused by the glucose dysregulation. In order to
prevent end-organ damage, such as cardiovascular complica-
tions, kidney failure, and cerebral complications, it is impor-
tant to define involved pathophysiological mechanisms.
Increased tissue advanced glycation endproducts (AGEs) play
an important role in these mechanisms [2] and may be used as
a biomarker of diabetes complications.
AGEs are formed in a multistep process by glycation and
oxidation of free amino groups in proteins, lipids, and nucleic
acids. These AGEs promote tissue dysfunction through cross-
linking of long-lived molecules and through binding to the
receptor for advanced glycation endproducts (RAGE) [3].
AGEs accumulate in the body during ageing, which results
in structural and functional tissue impairment. Formation and
accumulation of AGEs is accelerated in diabetes mellitus.
Furthermore, increased accumulation of AGEs occurs in sev-
eral other conditions, especially those associated with acute or
chronic oxidative stress. In renal failure, tissue AGE levels are
also increased due to impaired excretion of free AGEs and
AGE peptides [4].
In 1986, Monnier et al. [5] first presented evidence that
accumulation of AGEs in skin tissue was related to the pres-
ence of micro- and macrovascular complications in patients
with type 1 diabetes mellitus (T1DM). Later, the DCCT-
EDIC substudy on skin collagen glycation showed that
dermal tissue AGE levels predict long-term diabetes compli-
cations in T1DM, even after adjustment for HbA1c [6]. The
authors indicated that the damaging effect of AGEs in long-
lived protein molecules, such as collagen, may explain the
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phenomenon that they called Bmetabolic memory^: the
prolonged beneficial effects of intensive therapy and the del-
eterious effects of conventional, less stringent, therapy long
after cessation of the relatively brief intervention period. In
subsequent years, a range of experimental and clinical studies
confirmed this relation of increased levels of AGEs, both in
blood and slow-turnover tissues, with the presence of vascular
damage and complications in both T1DM and T2DM. The
United Kingdom prospective diabetes study (UKPDS) also
proposed AGEs as likely candidates to explain the effect of
metabolic memory [7].
However, assessment of AGEs in skin biopsy is not suit-
able for clinical use, because of the invasive method and high
costs. In 2004, a first report appeared that skin fluorescence,
non-invasively assessed, was related to AGE levels in dermal
biopsies in diabetes patients and in healthy controls [8]. The
dermal biopsies were obtained from the same measurement
site as in which skin fluorescence was performed and several
AGEs were determined using chromatographic and mass
spectrometric methods. The study pointed out that skin fluo-
rescence reflects dermal AGE levels and may be used as a
biomarker in AGE-related diseases. This review will discuss
the technique of skin fluorescence, its validation as a marker
of tissue AGE accumulation, and its use as a clinical tool for
the prediction of long-term complications in diabetes mellitus.
Technique of skin fluorescence measurement
So far, two devices have been used for assessment of skin
fluorescence in clinical studies: the AGE Reader
(DiagnOptics technologies BV, Groningen, the Netherlands)
and the SCOUT DS SF spectrometer (VeraLight, Inc.,
Albuquerque, NM, USA). Although both devices have been
developed to reflect skin AGE accumulation, the measure-
ment techniques differ, and the measurement values are not
directly comparable. Therefore, skin fluorescence as mea-
s u r e d by t h e AGE Read e r , p r e v i ou s l y c a l l e d
Autofluorescence Reader (AFR), will be referred to as skin
autofluorescence (SAF). Skin fluorescence as measured by
the SCOUT device will be referred to as skin intrinsic fluores-
cence (SIF). When general statements on either device are
made, the term ‘skin fluorescence’ will still be used.
SAF is measured on the volar side of the forearm. Care
should be taken to perform this measurement in an area with
normal skin with minimal sunlight exposure. The AGE
Reader contains a UV-A light emitting lamp that emits light
with a peak wavelength of 360–370 nm. Light reflected and
emitted in the 300–600 nm range from the skin is measured in
the research version by an inbuilt spectrometer, using a UV
glass fibre. In later, simpler versions, the spectrometer is re-
placed by a set of photodiodes with peak sensitivities for dif-
ferent wavelengths. Before every measurement, dark and
white reference readings are performed to correct for back-
ground light and to calculate reflectance, respectively.
Initially, SAF measurements were not considered for analysis
if the reflectance level was less than 10 %. After introduction
of more sophisticated and validated skin colour correction
software (version 2.3), this limit was lowered to 8 %. This
adaptation allowed the use of SAF in a broader group of per-
sons with dark skin colour. To correct for differences in light
absorption, SAF is calculated as a ratio of excitation light
(300–420 nm) to emitted light (420–600 nm). Consequently,
SAF is expressed in arbitrary units (AU). Intra-observer vari-
ation of repeated autofluorescence measurements is 5 % to
6 % within one day in different publications [8].
Although the exact molecular structures and the diversity
of species contributing to skin fluorescence are not
established, tissue fluorescent species have their own specific
excitation-emission spectrum. The used wavelength band of
the AGE Reader was selected such that the major contribution
in fluorescence comes from fluorescent AGEs. The majority
of identified AGEs are characterized by fluorescence in the
area around an excitation wavelength of 370 nm and an emis-
sion of 440 nm [9–11]. For example, the excitation spectrum
of pentosidine is 335 nm and its emission spectrum 385 nm
[12]. It was also investigated whether specific wavelengths
should be preferred over the currently used wavelength band
of the AGE Reader for differentiation between diabetic and
non-diabetic subjects or between diabetic subjects with and
without diabetes-related chronic complications. The authors
concluded that their results showed the validity of applying
a broad excitation wavelength range since no specific excita-
tion or emission wavelengths would yield an increased dis-
tinction between the different groups [13].
SCOUT measurements are performed on the inner side of
the forearm and are corrected for factors that affect light scat-
tering and absorption as well. SIF is excited with a light-
emitting diode (LED) centred at 375 nm, and the emission is
detected over 435–655 nm (with the reflectance adjusted by
the dimensionless excitation and emission exponents, kx = 0.6
and km = 0.2 respectively) [14]. In secondary analyses, SIF
measurements were examined using excitation LEDs centred
at 405 nm, 416 nm, 435 nm, and 456 nm. The VeraLight
company, which developed the SCOUT device specifically
for non-invasive diabetes detection, has suspended activities
2 years ago. Consequently, this device is no longer available.
Validation studies
Several validation studies have been conducted to determine
the performance of SAF as a tool for measuring dermal AGE
accumulation. First, SAF was compared with several specific
fluorescent and non-fluorescent AGEs in skin biopsies of di-
abetes patients and control subjects. Later, SAF was validated
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in a comparable way in renal failure and some other condi-
tions. Moreover, SAF was compared to another classical AGE
assay method for measuring AGEs, namely collagen-linked
fluorescence [8, 15, 16]. A combined analysis of the valida-
tion studies of SAF against dermal tissue AGE levels was
previously reported [17]. To illustrate, SAF had a correlation
coefficient of 0.87 with dermal tissue pentosidine levels in
biopsies from the same lower arm site, and so, SAF explained
76 % of the variance in dermal pentosidine levels [17].
SIF was originally based on a comparison of non-invasive
fluorescence spectroscopy and skin collagen AGEs (deter-
mined using chromatographic and mass spectrometric
methods) in a pig skin collagen model [18]. Further validation
was performed in a human subject study in which measure-
ments with an early SCOUT prototype were evaluated in di-
abetes versus control subjects. This study demonstrated that
SAGE, a skin derived skin fluorescence parameter, could ac-
curately classify disease in a case-control population [19].
However, SIF has not been validated in a direct com-
parison between skin fluorescence and dermal AGE levels in
human subjects.
Dark pigmentation, skin products, and other
influencing factors
A remark on the use of skin fluorescence deserves attention;
skin fluorescence measurements may be influenced by
dark pigmentation, the use of skin products, the fasting state,
and lifestyle factors.
For the AGE Reader, it has been demonstrated that SAF
levels show expected relations with calendar age and presence
of diabetes up to Fitzpatrick [20] skin phototype class IV. In
contrast, SAF levels may not be reliable in dark skin types
(Fitzpatrick class V-VI) [21, 22]. Therefore, ongoing studies
with the AGE Reader address and aim to resolve the limita-
tions in the use of SAF in people with dark skin types.
Several skin products may affect the measurement of SAF,
especially sunscreens and skin tanners. However, some con-
ventional skin creams may also make the measurement unre-
liable. When possible, persons should be asked to avoid use of
skin products several days before a SAF measurement.
Otherwise, persons should be asked about recent use of skin
products [23].
An increase in SAF was seen 2 h postprandial in a study
performed by Stirban et al. [24]. This may suggest that blood
AGEs and redox-regulated fluorophores from skin micro ves-
sels contribute to SAF in addition to skin-bound compounds.
Therefore, it was suggested that performance of SAF in the
fasting state might improve the sensitivity and specificity of
the method. Although we should keep this in mind, the post-
prandial increase in SAF was limited (10 %) and not seen in
all patients. Moreover, it is not clinically preferable to perform
SAF in the fasting state, and most current knowledge
concerning SAF, including its validation, has been acquired
in patients irrespective of their fasting state. Furthermore, in a
study where food intake was not restricted, the variation of
SAF over the day was 5 % [25]. Therefore, it is not generally
recommended to perform SAF after an overnight fast.
As AGEs accumulate over time, SAF increases with aging
[21]. In addition, SAFmay be influenced by other clinical and
lifestyle factors, such as kidney function [26] and smoking
[27]. Recently, an integrated analysis of both lifestyle and
clinical factors has been performed in a large-scale non-dia-
betic population and a T2DM subpopulation [28]. The results
show that 34 % of the variance in SAF was explained
by age, body mass index, HbA1c, creatinine clearance, N-
acetyltransferase 2 polymorphism, (pack-years of) smoking,
and coffee consumption. In the T2DM population, 47% of the
variance in SAF was explained by the same factors except for
coffee consumption.
For the SCOUT device, it was claimed that the skin colour
range, in which reliable measurements could be made, was
somewhat broader than for the AGE Reader. In subjects at risk
for T2DM, it is observed that SIF measurements are not major-
ly influenced by the fasting status since the variation (5.7%) for
fasting subjects (pre-glucose challenge versus post-glucose
challenge) was comparable to the variation (5.5 %) for two
non-fasting measurements [29]. Clinical and technical factors
influencing SIF were investigated in 1185 T1DM patients. The
results show that 33 % of the variance in SIF was explained by
age, HbA1c, estimated glomerular filtration rate, smoking, skin
tone, and clinic latitude [30]. Later, caffeine consumption was
also found to contribute to SIF in the same cohort [31]. To the
best of our knowledge, there are no reports concerning the
influence of skin products on SIF.
Skin fluorescence in diabetes screening
Skin fluorescence has been proposed to be useful as a cost-
effective, simple, and reproducible test for diabetes screening
[32]. In subjects with intermediate risk for developing T2DM, a
SAF based decision tree was shown to have a similar or supe-
rior diagnostic performance for impaired glucose tolerance and
diabetes in comparison with fasting plasma glucose, HbA1c,
and the FINDRISC questionnaire [33]. The authors suggested
that the decision tree could be used for selective or targeted
screening for early diabetes in groups with increased risk.
Cut-off values for SAF would be ≥80th (< 50 years) or ≥70th
(≥ 50 years) age percentile, based on previously published ref-
erence values [21], for which patients should be referred for
oral glucose tolerance tests. For the SCOUT device, a few
studies have shown that SIF had a similar or superior perfor-
mance to fasting plasma glucose, HbA1c, and/or capillary glu-
cose in detecting abnormal glucose tolerance [29, 34, 35].
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Relations between SAF and AGE levels in different
tissues
Dissociation of SAF and plasma AGEs
In several studies, SAF levels are poorly related to simulta-
neously measured plasma or blood glycation markers
[36–38]. The difference in turnover rate of skin and plasma
proteins provides an obvious explanation. Accumulation of
AGEs strongly depends on tissue turnover since AGEs are
mainly irreversibly linked to tissue proteins. Turnover of col-
lagen and elastin in the skin is very slow, with an estimated
lifetime of dermal skin collagen of 10–15 years [39].
Therefore, dermal AGEs capture decades-long glycaemia. In
contrast, AGEs derived from tissues with fast turnover (such
as plasma, epidermis, and mucosa) are rapidly broken down to
AGE peptides and/or free AGEs, which are excreted through
the kidney. To illustrate, the conventional HbA1c glycation
marker assay reflects a glycaemic period of 12 to
16 weeks. Some studies have shown that the poor rela-
tion of SAFwith current HbA1c levels improveswhen a series
of HbA1c levels, integrated over longer periods back in time
(also mentioned as past long-term glycaemic control), are used
[40–42].
Associations between SAF and tissues with slow turnover
Examples of tissues with slow turnover are the eye lens, car-
tilage, cardiac tissue, and most brain cell/interstitial tissue
types. Structural proteins in the eye lens remain lifelong pres-
ent from 2–3 months after conception, while new proteins are
only slowly added from the exterior part. Januszewski et al.
[43] found that SAF and ocular (lens and cornea) fluorescence
were elevated in T1DM compared to controls. Moreover SAF
was correlated to lens- and cornea fluorescence in both non-
diabetic and T1DM subjects. Hofmann et al. [44] reported a
close correlation between SAF and tissue AGE levels of the
atrial appendage. Both were associated with age and short-
and long-term glucose levels in patients with coronary artery
disease. These results provide evidence for a relation between
SAF and cardiac tissue glycation.
Micro - andmacrovascular complications in diabetes
AGE reader
Bos et al. [45] performed a systematic review of SAF and
diabetes complications in 2011. The authors included studies
in which patients participated with T1DM or T2DM, in
which SAF levels were measured by the AGE Reader or
its prototype (AFR), and in which information was drawn
concerning complications of diabetes. In total, four cross-
sectional studies [27, 46–48] and 3 prospective studies
[49–51] met their inclusion criteria. In all seven studies, a
positive association between SAF and one or more diabetes
complications (all-cause mortality, cardiovascular mortality,
micro- and macrovascular complications, neuropathy, and ne-
phropathy) was seen, except for retinopathy. At that time, Bos
et al. [45] concluded that these results should be interpreted
with caution because studies were of large clinical heteroge-
neity, most studies included small numbers of subjects, and 5
of the 7 studies were from the same research group.
Furthermore, all of these studies were performed in Europe,
therefore, mainly including Caucasian subjects.
Recently, more studies confirmed the positive association
between SAF and one or more complications. Four (cross-
sectional) studies showed an independent relation between
SAF and both micro- and macrovascular complications in
T2DM [52–55]. Ahdi et al. [52] demonstrated that SAF was
a stronger determinant for these complications than HbA1c in
patients with fair skin colours, but not in patients with darker
skin colour types (mainly Hindustani and Africans). Tanaka et
al. [55] were first to describe that SAF was independently
associated with the presence of micro- and macrovascular
complications in a non-Caucasian (Japanese) population.
Later, Liu et al. [53] confirmed this association in Chinese
patients with diabetic foot ulcer. The authors found that SAF
was independently associated with the occurrence of all the
reported vascular diseases (retinopathy, nephropathy, periph-
eral neuropathy, coronary heart disease, cerebrovascular dis-
ease, peripheral artery disease), except for diabetic peripheral
neuropathy. Finally, Noordzij et al. [54] showed that SAF was
independently associated with the presence of both micro- and
macrovascular complications in a multi-centre study per-
formed in 5 Dutch hospitals.
Regarding diabetic retinopathy, two Japanese studies spe-
cifically investigated the relationship between SAF and the
severity of the disease in T2DM [56, 57]. Both studies report-
ed a positive association that remained significant after adjust-
ment for (among others) age, HbA1c, diabetes duration, sys-
tolic blood pressure, and serum creatinine or presence of dia-
betic nephropathy. Moreover, the authors concluded that SAF
was a better diagnostic marker for diabetic retinopathy com-
pared to HbA1c. Hirano et al. [57] further reported that SAF
was not correlated with diabetic macular oedema, neither was
HbA1c or self-assessed diabetes duration.
In T1DM, four (cross-sectional) studies reported the rela-
tion of SAF with retinopathy, nephropathy, and/or neuropathy
in the past 5 years [42, 58–60]. Except for one [58], all studies
investigating retinopathy showed a significant correlation
with SAF after correction for (at least) age [42, 59, 60]. With
regard to nephropathy, all four studies showed some positive
result. In one study [58], however, the positive association
disappeared in multivariate analysis. Furthermore, it is impor-
tant to mention that different definitions of the outcome have
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been used to detect nephropathy in these studies. The two
studies investigating neuropathy both showed an inde-
pendent relationship of SAF with neuropathy in multivariate
analyses [58, 59].
In summary, these recent reports (performed by several
research groups in different racial groups) show consistent
evidence of an association between SAF and end-organ com-
plications in diabetes. Several studies have now confirmed
that SAF is associated with retinopathy, even after correction
for age and nephropathy. In addition, a few studies established
an independent association between SAF and vascular com-
plications in diabetes patients of Asian descent. However, no
relation was found between SAF and vascular complications
in diabetes patients with darker skin colour types.
Unfortunately, none of the recent studies had a prospective
design, but from earlier studies, some evidence remains for
the predictive value of SAF in the development of diabetes
complications in T2DM [49, 50]. Therefore, prospective stud-
ies with long period of follow-up and large group size are still
needed to establish the role and potential benefit of SAF in
disease management of diabetes patients, especially in T1DM.
SCOUT device
Three (cross-sectional) studies have been performed in which
the association between SIF and diabetes complications is
investigated [61–63]. All studies were performed in T1DM.
First, Conway et al. [61] reported that SIF was more strongly
associated with autonomic and distal symmetrical
polyneuropathy compared to HbA1c. Later, Conway et al.
[62] showed that SIF was significantly associated with coro-
nary artery disease (CAD) after correction for age, diabetes
duration, mean HbA1c, and sex. The authors concluded that
SIF may be a useful overall marker of CAD risk in T1DM.
Finally, Orchard et al. [63] investigated the association be-
tween SIF and complications in the DCCT/EDIC study.
They found moderately strong associations with all complica-
tions. After adjustment for mean HbA1c, these associations
remained significant for cardiac autonomic neuropathy, ne-
phropathy, and coronary artery calcification in the con-
ventional treatment group and became non-significant
for all complications in the intensive treatment group.
Orchard et al. [63] concluded that prospective studies are
needed to fully evaluate the predictive value of SIF in the
development of complications.
SAF and clinical markers of cardiovascular disease
Supporting the association between SAF and cardiovascular
complications, SAF has been related to several clinical
markers of cardiovascular disease: diastolic function, arterial
compliance, markers of endothelial function, and markers of
atherosclerosis. A relation between SAF and functional ana-
tomical changes, reflected in diastolic dysfunction, was first
shown in a study by Hartog et al. [38] in patients with renal
failure. Other studies have described the association between
dermal or plasma AGEs and diastolic dysfunction [64, 65].
Several studies have shown that SAF is related to arterial
compliance evaluated by arterial pulse wave velocity (aPWV).
Ueno et al. [66] and Januszewski et al. [43] described a rela-
tion between SAF and aPWV in end stage renal failure and in
diabetes patients, respectively. Similar relations were found in
various patient groups by Watfa et al. [67], de Groot et al.
[68], and Llaurado et al. [69]. In accordance with these stud-
ies, de Boer et al. [70] recently reported that SAF was associ-
ated with aPWV in recently diagnosed T2DM patients. In the
same patient group, SAF was related to arterial calcification
scores, although aPWV was not.
Relations between SAF and markers of microvascular and
endothelial function have been described mainly in diabetes
and renal failure patients. Araszkiewicz et al. [71] found a
relation between SAF and microvascular reactivity, as
assessed by peak flow after reactive hyperaemia mea-
sured by laser Doppler flow. Furthermore, Ueno et al. [72]
observed a negative relation between SAF and circulating
endothelial progenitor cells.
In earlier studies, it had already been shown that AGEs
measured in skin samples using collagen fluorescence are as-
sociated with coronary calcium score, as a surrogate marker
for coronary atherosclerosis. More recently, SAF has been
reported to be associated with clinical markers of atheroscle-
rosis, such as intima media thickness and coronary calcifica-
tion score, by several groups [59, 73–75]. The relation of SAF
and AGEs with calcification not only exists for coronary ar-
teries, but also with medial artery calcification in peripheral
arteries [76].
Other prevalent conditions in diabetes
Vascular complications are common and receive much atten-
tion in diabetes research. More recently, diabetes have also
been linked to other disorders, such as impaired cognitive
function, Alzheimer’s disease [77], and depression [78].
Evidence exists that (small) vessel disease and reduced arterial
compliance are linked to these complications. Recently, stud-
ies have also addressed the question whether SAF is linked to
these disorders.
Spauwen et al. [79] reported inverse associations between
SAF and cognitive performance. These associations were atten-
uated after adjustment for vascular risk factors and depression,
but remained significant for delayed word recall and response
inhibition and became non-significant for global cognitive
functioning, immediate word recall, and information process-
ing speed. These associations did not differ between individuals
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with and without T2DM. The authors concluded that AGEs
may be involved in the development of cognitive decline, es-
pecially memory decline, partly through the action of vascular
risk factors. Besides cognitive performance, SAF has also been
associated with structural changes in the brain, namely lower
grey matter volume [80]. Moran et al. [80] demonstrated that
these results support further research into the role of AGEs in
the pathogenesis of dementia in relation to T2DM.
Van Dooren et al. [81] showed that SAF is independently
associated with presence of depressive disorders and symp-
toms of depression, both cognitive and somatic. These results
did not differ between individuals with or without T2DM. The
authors suggested that AGEs might be involved in the devel-
opment of depression.
Future perspectives
Diabetes has been shown to be a risk factor for retinal detach-
ment after cataract surgery [82]. In a pilot study, our research
group has recently shown that SAF was related to the severity
of retinal detachment [83]. Soon, we will report the results of a
prospective cohort study in which we investigated whether
SAF and/or vitreous AGEs predict surgical failure in retinal
detachment patients.
AGEmeasurements, SAF in particular, have been included
in some large cohorts, such as the Maastricht study [84]
(enriched with diabetes patients) and LifeLines [85]. These
and other studies, such as the Derby CKD study [86–88], will
provide more insight in the links between AGEs and other
aging and disease mechanisms, especially when longer term
follow-up data become available. Currently, our research
group is investigating the performance of SAF in detecting
abnormal glucose tolerance in a large population-based cohort
study (LifeLines).
Conclusion
It has been extensively shown that skin fluorescence is asso-
ciated with a wide variety of long-term complications in dia-
betes mellitus. This association is supported by the relation
between skin fluorescence and AGE accumulation in several
tissues with slow turnover, between skin fluorescence and past
long-term glycaemic control, and between skin fluorescence
and clinical markers of cardiovascular disease. A limited num-
ber of studies have also provided evidence for an independent
predictive role of skin fluorescence for cardiovascular compli-
cations and mortality in diabetes. More prospective studies,
with longer follow-up period and larger group size, are
being conducted to establish the predictive role and po-
tential benefit of skin fluorescence in disease management of
diabetes patients.
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